



UNIVERSITÀ POLITECNICA DELLE MARCHE  
Repository ISTITUZIONALE

A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: The MaPLE randomised controlled trial

This is the peer reviewed version of the following article:

*Original*

A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: The MaPLE randomised controlled trial / Del Bo', C.; Bernardi, S.; Cherubini, A.; Porrini, M.; Gargari, G.; Hidalgo-Liberona, N.; Gonzalez-Dominguez, R.; Zamora-Ros, R.; Peron, G.; Marino, M.; Gigliotti, L.; Winterbone, M. S.; Kirkup, B.; Kroon, P. A.; Andres-Lacueva, C.; Guglielmetti, S.; Riso, P.. - In: CLINICAL NUTRITION. - ISSN 0261-5614. - STAMPA. - 40:5(2021), pp. 3006-3018.  
[10.1016/j.clnu.2020.12.014]

*Availability:*

This version is available at: 11566/330398 since: 2024-08-05T09:14:18Z

*Publisher:*

*Published*

DOI:10.1016/j.clnu.2020.12.014

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. The use of copyrighted works requires the consent of the rights' holder (author or publisher). Works made available under a Creative Commons license or a Publisher's custom-made license can be used according to the terms and conditions contained therein. See editor's website for further information and terms and conditions.

This item was downloaded from IRIS Università Politecnica delle Marche (<https://iris.univpm.it>). When citing, please refer to the published version.

(Article begins on next page)



1 **A polyphenol-rich dietary pattern improves intestinal permeability in older subjects: the MaPLE**  
2 **randomised controlled trial**

3

4 Cristian Del Bo<sup>1§</sup>, Stefano Bernardi<sup>1§</sup>, Antonio Cherubini<sup>2</sup>, Marisa Porrini<sup>1</sup>, Giorgio Gargari<sup>1</sup>, Nicole  
5 Hidalgo-Liberona<sup>3,4</sup>, Raúl González-Domínguez<sup>3,4</sup>, Raul Zamora-Ros<sup>3,5</sup>, Gregorio Peron<sup>3,4</sup>, Mark S  
6 Winterbone<sup>6</sup>, Benjamin Kirkup<sup>6</sup>, Paul A Kroon<sup>6</sup>, Cristina Andres-Lacueva<sup>3,4</sup>, Simone Guglielmetti<sup>1</sup>,  
7 Patrizia Riso<sup>1\*</sup>

8

9 **Affiliations**

10 <sup>1</sup>Università degli Studi di Milano, Department of Food, Environmental and Nutritional Sciences  
11 (DeFENS), 20133 Milan, Italy; <sup>2</sup>Geriatrics, Accettazione Geriatrica e Centro di Ricerca per  
12 l'Invecchiamento, IRCCS INRCA, 60127 Ancona, Italy; <sup>3</sup>Biomarkers and Nutrimetabolomics  
13 Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Faculty of Pharmacy and Food  
14 Sciences, University of Barcelona, 08028 Barcelona, Spain; <sup>4</sup>CIBER de Fragilidad y Envejecimiento  
15 Saludable (CIBERfes), Instituto de Salud Carlos III, 08028 Barcelona, Spain; <sup>5</sup>Unit of Nutrition and  
16 Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge  
17 Biomedical Research Institute (IDIBELL), Spain; <sup>6</sup>Quadram Institute Bioscience, Norwich Research  
18 Park, Norwich NR4 7UQ, United Kingdom

19

20 §equally contributed as first author

21 \*Corresponding author: [patrizia.riso@unimi.it](mailto:patrizia.riso@unimi.it)

22

23

24

25

26

27 **ABSTRACT**

28 **Background & aim:** Increased intestinal permeability (IP) can occur in older people and contribute to  
29 the activation of the immune system and inflammation.

30 Dietary interventions may represent a potential strategy to reduce IP. In this regard, specific food  
31 bioactives such as polyphenols have been proposed as potential IP modulator due to their ability to  
32 affect several critical targets and pathways that control IP.

33 The trial aimed to test the hypothesis that a polyphenol-rich dietary pattern can decrease IP and  
34 beneficially alter IP-associated biochemical and clinical markers in older subjects.

35 **Methods:** A randomised, controlled, cross-over intervention trial was performed. Sixty-six subjects  
36 (aged  $\geq 60$  y) with increased IP based on serum zonulin levels, were randomly allocated to one of the  
37 two arms of the intervention consisting of a control diet (C-diet) vs. a polyphenol-rich diet (PR-diet).  
38 Each intervention was 8-week long and separated by an 8-week wash out period. At the beginning and  
39 at the end of each intervention period, serum samples were collected for the quantification of zonulin  
40 and other biological markers. In addition, anthropometrical/physical/biochemical parameters and food  
41 intake were evaluated.

42 **Results:** Fifty-one subjects successfully completed the intervention and a high compliance to the  
43 dietary protocols was demonstrated. Overall, polyphenol intake significantly increased from a mean of  
44 812 mg/day in the C diet to 1391 mg/day in the PR-diet. Two-way analysis of variance showed a  
45 significant effect of treatment ( $p = 0.008$ ) and treatment  $\times$  time interaction ( $p = 0.025$ ) on serum zonulin  
46 levels, which decreased after the 8-week PR-diet. In addition, a treatment  $\times$  time interaction was  
47 observed, showing a reduction of diastolic blood pressure ( $p = 0.028$ ) following the PR-diet, that was  
48 underlined in women ( $p = 0.043$ ) showing also a decrease of systolic blood pressure ( $p = 0.042$ ).

49 A trend towards a reduction of total cholesterol was observed (time effect,  $p = 0.039$ ) following both  
50 interventions. The efficacy of this dietary intervention was higher in subjects with higher serum zonulin  
51 at baseline, who showed more pronounced alterations in the markers under study. Furthermore, zonulin

52 reduction was also stronger among subjects with higher body mass index and insulin resistance at  
53 baseline, thus demonstrating the close interplay between IP and metabolic features.

54 **Conclusions:** These data show, for the first time, that PR-diet can reduce IP evaluated as serum  
55 zonulin levels. These findings may represent an initial breakthrough for further intervention studies  
56 evaluating possible dietary treatments for the management of IP in different target populations.

57 This study was registered at [www.isrctn.org](http://www.isrctn.org) as ISRCTN10214981

58

59 **Keywords:** zonulin; leaky gut; inflammation; flavonoids; phenolics; aging

## 60        **1. Introduction**

61        The integrity of the intestinal barrier is fundamental for gut and human health. This barrier is  
62        maintained thanks to the active involvement of “tight junctions”, in which multiprotein complexes  
63        serve to seal the junctions between epithelial cells. Tight junctions control mucosal permeability and  
64        act as intermediates/transducers in cell signalling cascades [1]. The layer of epithelial cells represents  
65        a physical barrier against external factors, including microbial factors, while maintaining a controlled  
66        symbiosis with commensal bacteria [2]. The disruption of the junctions between epithelial cells results  
67        in increased intestinal permeability (IP), also known as “leaky gut”. It enables the translocation of  
68        microorganisms and/or microbial derived factors from the intestinal lumen to the blood stream, leading  
69        to the activation of immune function and inflammation [3]. An increased IP has been proposed as a  
70        potential contributor to a wide range of intestinal disorders such as irritable bowel syndrome, and  
71        inflammatory bowel, and coeliac diseases. In addition, recently, increased IP has also been proposed  
72        as a potential cause of age-related conditions [4]. In fact, age has reported as an independent risk factor  
73        for altered IP [5], and some studies have shown an increased IP over the age of 50 y due to a potential  
74        progressive process of deterioration in the functions and integrity of the intestinal barrier [5]. During  
75        aging, an increased IP may contribute to the onset of chronic low-grade inflammation, also known as  
76        inflamm-aging [6,7], responsible of the higher risk of several age-related diseases including metabolic  
77        syndrome, obesity, diabetes and cardiovascular diseases. Gut microbiota seems to play a central role  
78        in driving inflamm-aging, as it can release several inflammatory factors, and contribute to IP  
79        (dys)regulation [8,9]. For example, gut microorganisms may act directly on IP by affecting tight  
80        junction functionality and/or indirectly by modulating inflammation [4]. Consequently, the  
81        manipulation of gut microbiota has been proposed as a potential novel strategy to improve IP. Dietary  
82        patterns and specific food bioactives are considered important factors capable to manipulate and shape  
83        gut microbiota, which can positively or negatively affect IP. Recent studies discussed the role of several  
84        macro and micronutrients in the modulation of IP. The results highlighted that an excessive energy  
85        intake, high-fat, high-sugar and high-animal protein consumption, as well as alcohol intake are

86 associated with an alteration of the intestinal microbial ecosystem and an increased IP [10-12].  
87 Moreover, an inadequate nutrient intake (e.g. low protein intake) that often occurs in older subjects can  
88 contribute to increase IP [4]. Conversely, diets rich in low-energy dense foods (e.g. fruits and  
89 vegetables) and fibres have been associated with a healthier gut microbiota and a reduced IP [13]. In  
90 the context of a diet-microbiota-IP axis, several food bioactives, including polyphenols, may represent  
91 a potential strategy to positively affect microbiota composition and to improve IP and related  
92 conditions [14]. Polyphenol biological functions include antioxidant and anti-inflammatory properties,  
93 and immunomodulatory activity at both intestinal and systemic levels [2]. Despite the exact molecular  
94 mechanisms are not completely understood, polyphenols may directly and/or indirectly act at different  
95 levels of the intestinal barrier by regulating tight junction function, the production of numerous  
96 inflammatory cytokines and the activation of antioxidant genes [2]. Furthermore, polyphenols undergo  
97 extensive modifications by the gut microbiota and, consequently, affect the intestinal microbial  
98 ecosystem. For such reasons, polyphenols could represent elective bioactives to develop dietary  
99 intervention strategies to counteract detrimental effects of IP.

100 To the best of our knowledge, human intervention studies aimed at investigating the role of polyphenols  
101 in the modulation of IP are still lacking. Within this context, the MaPLE (Microbiome mAnipulation  
102 through Polyphenols for managing Leakiness in the Elderly) randomised, controlled, crossover trial  
103 was designed to assess whether a high intake of polyphenol-rich foods in older subjects would reduce  
104 IP and improve markers of inflammation and vascular function.

## 105 106 **2. Materials and Methods**

### 107 *2.1 Setting and subjects' recruitment*

108 The MaPLE trial was carried out at Civitas Vitae (OIC Foundation, Padua, Italy), an institution  
109 including residential care and independent residences for older subjects. The setting was selected in  
110 order to enable a significant control of most of the experimental variables affecting dietary intervention  
111 studies as previously described [15]. Subjects selection was performed in collaboration with physicians

112 and staff at OIC Foundation, based on medical examination and the evaluation of drug therapies. The  
113 final eligibility was defined according to the inclusion and exclusion criteria reported below.  
114 To be included in the trial, the subjects had to be  $\geq 60$  years old, with an adequate nutritional status, a  
115 good cognitive status, good functional autonomy, and with an increased IP evaluated as serum zonulin  
116 level concentrations by considering reference values and other literature as previously detailed [15-  
117 18]. Exclusion criteria included: having Celiac disease, advanced stage of chronic diseases such as  
118 cirrhosis, renal insufficiency (dialysis), severe Chronic Obstructive Pulmonary Disease (COPD) or  
119 severe cardiovascular disease (heart failure class III or IV NYHA - New York Heart Association).  
120 Moreover, subjects with malignant tumours that required treatment in the previous 2 years were  
121 excluded as well as those treated with antibiotics in the last month before the intervention period.  
122 The entire process of subject selection and randomization within the clinical trial is reported in **Figure**  
123 **1**. The study protocol complied with the principles of the Declaration of Helsinki and was approved by  
124 the Ethics Committee of the University of Milan, Italy (ref: 6/16/CE\_15.02.16\_Verbale\_All-7). All  
125 participants were informed about the study protocol and they signed an informed consent before the  
126 enrolment. The trial was registered under ISRCTN.com (ISRCTN10214981).

## 127 *2.2 Definition and set up of the dietary intervention*

128 The dietary intervention protocol was developed following an initial evaluation of the nutrient  
129 composition (through MetaDieta® software by Me.Te.Da S.r.l., San Benedetto del Tronto, Italy) and  
130 total polyphenol content (mainly through Phenol-Explorer.eu database) of the daily menu provided  
131 by OIC Foundation to the host. The development of the polyphenol-rich (PR) dietary pattern was  
132 designed by the substitution of some low-polyphenol products in the control diet (C-diet) with other  
133 comparable PR-products (e.g. foods used for snack or breakfast) and maintaining as much as possible  
134 the overall energy and nutrient composition. Specifically, subjects consumed three small portions per  
135 day of the following selected PR-foods: berries and related products, blood orange and juice,  
136 pomegranate juice, green tea, Renetta apple and purée, and dark chocolate (callets and cocoa powder-  
137 based drink), which provided a mean of 724 mg/day of total polyphenols estimated by Folin-



138 Ciocalteu analysis [19]. Thus, the total polyphenol intake in the intervention diet, i.e. including the  
139 menu plus the PR-foods, was roughly doubled compared to the C-diet.

140 A schematic plan of the type and serving sizes of PR-foods consumed daily within the intervention has  
141 been reported previously [15].

142

### 143 *2.3 Experimental design*

144 The trial consisted of an 8-week, randomised, repeated measure cross-over intervention study (i.e. PR-  
145 diet vs C-diet). Volunteers were randomly allocated in one of the two arms of the intervention starting  
146 with PR-diet or C-diet according to a computerized randomization protocol [15]. Subjects assigned to  
147 the PR-diet received the 3-daily portions of selected PR-products described before. During the C-diet  
148 period, subjects followed the regular menus provided by the nursing home that were previously  
149 evaluated for their nutritional composition. After a wash-out period (8 weeks) performed to avoid any  
150 carry-over effect, the groups were switched to the other treatment.

151 At the beginning and at the end of each intervention periods all participants underwent to physical and  
152 general condition examinations (i.e. height, weight, blood pressure and clinical signs). In addition,  
153 biological samples were collected for the analysis of metabolic and functional markers.

154

### 155 *2.4 Compliance*

156 To ensure adequate compliance to the dietary intervention protocol PR-rich foods, that were in part or  
157 completely not consumed, were registered at the end of each day. In addition, weighted food diaries  
158 were filled in during the trial to assess the adherence to both dietary treatments (PR- and C- diet) [15].

159

### 160 *2.5 Anthropometrical and physical evaluations*

161 Height and weight were measured according to Lohman et al international guidelines [20]; body mass  
162 index (BMI) was calculated according to the formula – weight (kg)/height (m<sup>2</sup>). Reference scores were

163 defined according to international guidelines [20]. Blood pressure was obtained in resting, seated  
164 position following the JNC 7 guidelines [21].

165

## 166 *2.6 Blood sampling and analysis*

167 After an overnight fast, blood samples were drawn in Vacutainer tubes containing silicon gel for serum  
168 and maintained at room temperature for at least 30 min. Serum was then obtained by tube centrifugation  
169 (1400 g x 15 min, 4°C), splitted in small aliquots into specific vials and stored at -80°C until analysis.  
170 Samples were used for the evaluation of several metabolic and functional parameters [15].

171 In particular, glucose, insulin, lipid profile (total cholesterol, triglycerides), liver and renal function  
172 (i.e. aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, creatinine)  
173 were analysed using a standardized routine-use automatic biochemical analyser (ILAB 650,  
174 Instrumentation Laboratory, Lexington, MA). Serum concentration of low-density lipoprotein  
175 cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) were estimated by using  
176 the Friedewald formula [22] and by subtracting HDL-C from total cholesterol (TC), respectively. In  
177 addition, the homeostasis model assessment of insulin resistance (HOMA-IR) was performed, and  
178 values > 3 were considered as a criterion for insulin resistance [23]. The Cockcroft-Gault (C-G) index  
179 based on creatinine clearance was calculated according to the formula previously defined in literature  
180 [24,25].

181

## 182 *2.7 Evaluation of IP*

183 Serum samples for IP evaluation (at recruitment and at each time point of intervention) were defrosted  
184 at room temperature and serum zonulin level was assessed by using the Immunodiagnostik® ELISA  
185 kit (Bensheim, Germany). The assay, based on a competitive Elisa method, consisted in the addition  
186 to each sample (including standard and control samples) of a biotinylate zonulin tracer (at first step)  
187 and the use of a pre-coated 96-well plate with polyclonal anti-zonulin antibody. The peroxidase-  
188 labelled streptavidin addition was used to bind the biotinylate zonulin tracer. After the reaction, the

189 plate reader TECAN Infinite F200 (Tecan Group Ltd. Mannedorf, Switzerland) was used to read the  
190 fluorescence at 450 nm. Serum zonulin concentrations were quantified by using a standard curve  
191 calculated by a 4-parameter algorithm as reported by the manufacturer.

192

### 193 *2.8 Evaluation of inflammatory markers*

194 C-reactive protein (CRP), Tumour Necrosis Factor  $\alpha$  (TNF- $\alpha$ ) and interleukin-6 (IL-6) levels were  
195 quantified using specific ELISA kits (R&D Systems, Biotechne, Abingdon, UK). Specifically, CRP  
196 (DCRP00), IL-6 (HS600B), and TNF- $\alpha$  (HSTA00E) were quantified in serum at the beginning and  
197 the end of each intervention period.

198

### 199 *2.9 Evaluation of vascular markers*

200 Serum samples at each time point were used to quantify vascular cell adhesion molecule-1 (VCAM-1)  
201 and intercellular adhesion molecule-1 (ICAM-1) by using an ELISA kit (Booster® from Vinci  
202 Biochem S.r.l., Vinci, Italy). After competitive treatment with antibodies and fluorophore, fluorescence  
203 was read by a TECAN Infinite F200 plate reader. A 4-parameter algorithm was used to create the  
204 standard curve and to calculate serum concentrations.

205

### 206 *2.10 Statistical analysis*

207 Sample size was calculated based on previous published data [18,26]. It was estimated that 50 subjects  
208 were needed to detect a 30% decrease in plasma zonulin with 80% power and  $\alpha=0.05$  with an  
209 estimated drop-out rate of 15%.

210 Differences between treatments were computed by ANOVA for repeated measures design (using the  
211 Least Significant Difference - LSD test - as post hoc analysis to evaluate differences among means).  
212 In addition, although a relatively high zonulin level was used as an inclusion criterion [15], we found  
213 interesting to verify whether the response to dietary treatments could differ in subjects stratified with  
214 respect to median serum zonulin levels at baseline, as it was also reported in recent publications [9,10].

215 Specifically, subjects were stratified in two groups: LSZ group (lower serum zonulin levels; i.e.  $\leq$   
216 median value) and HSZ group (higher serum zonulin levels; i.e.  $>$  median level). The regression and  
217 correlation analyses (Spearman and Kendal test) were carried out to highlight associations between  
218 zonulin levels (HSZ vs LSZ) and physiological and biochemical parameters. In addition, a further  
219 statistical analysis in which subjects were stratified in two groups based on median values for BMI and  
220 HOMA-index was performed in order to investigate the contribution of metabolic characteristics on IP  
221 and related markers. Potential gender differences were also considered in the analyses. Significance  
222 was set at  $p \leq 0.05$ . P values in the range  $0.05 < p < 0.10$  were considered as trends. All analyses were  
223 performed using the R statistic software version 3.4.2.

224

## 225 3. Results

### 226 3.1 Recruitment phase workflow

227 Of the initial 491 older subjects considered, 349 were excluded after evaluation by OIC physicians  
228 since they did not meet the inclusion criteria and 70 subjects declared not to be interested into  
229 participate for personal reasons. A total of 72 subjects were further screened and 3 subjects were  
230 excluded for low serum zonulin levels. Difficulty in drawing blood was the reason for excluding others  
231 3 subjects.

232 Finally, 66 subjects (27 men, 39 women) were enrolled in the trial, but only 51 subjects completed the  
233 entire intervention study. A schematic flowchart of the protocol, reporting all the information from the  
234 recruitment until the end of the study, is shown in **Figure 1**.

235

### 236 3.2 Baseline characteristics of the participants

237 The main characteristics at baseline of the 51 subjects who completed the study protocol are provided  
238 in **Table 1**. Age ranged between 60 and 98 years old with a median value of 77 years old. Age

239 distribution was comparable in men and women. A high inter-individual variability was observed for  
240 several markers and in particular BMI (IQR: 22.5;30.7), glucose (IQR: 86;113) and total cholesterol  
241 levels (IQR 167;242).

242

### 243 *3.3 Correlation analysis of subjects' characteristics based on HSZ or LSZ at baseline*

244 Serum zonulin levels were positively correlated with creatinine ( $p = 0.033$ ) and triglycerides ( $p =$   
245  $0.004$ ) considering all participants (**Figure 2A**). However, the correlation of zonulin with creatinine  
246 clearance, as C-G index, was not significant. A positive correlation was evidenced among  
247 inflammatory markers (i.e. IL-6, TNF- $\alpha$ , CRP); in addition, a positive correlation emerged between  
248 CRP levels and BMI ( $p = 0.021$ ), and TNF- $\alpha$  and TG ( $p = 0.0009$ ) (**Figure 2A**).

249 When subjects were stratified according to high *versus* low serum zonulin levels at baseline, HSZ  
250 group showed a positive correlation between zonulin and HOMA index ( $p = 0.037$ ), and creatinine ( $p$   
251  $= 0.025$ ) (**Figure 2B**). This last correlation was not confirmed when C-G index was used. Regarding  
252 LSZ subjects, no significant correlation was observed between serum zonulin levels and the other  
253 markers under study (**Figure 2C**).

254

### 255 *3.4 Compliance to the dietary intervention*

256 The nutrient composition of the diet consumed by participants during both treatment periods is reported  
257 in **Table 2**. A comparable pattern of food consumption was evidenced, except for the PR-products  
258 provided in the PR-diet. Energy and overall composition of the diet did not differ in the two periods of  
259 intervention (PR-diet *vs* C-diet). Following the PR-diet a small decrease in animal proteins and lipids  
260 and an increase in carbohydrates and fibre intake (less than 1 g as a mean) was observed with respect  
261 to the C-diet. Overall, a high adherence to the dietary protocol was registered: the subjects accepted  
262 and easily consumed all the PR-products provided daily and no adverse effects were reported. On the  
263 whole, during the PR-diet treatment subjects increased their total polyphenol intake by approximately  
264 70% (**Table 2**).

265 *3.5 Effect of dietary interventions on markers under study*

266 **Table 3** shows the results concerning anthropometrical and physical characteristics, biochemical,  
267 inflammatory and vascular markers evaluated before and after each treatment.

268 A treatment  $\times$  time interaction was observed for diastolic blood pressure ( $p = 0.024$ ) and uric acid levels  
269 ( $p = 0.034$ ). Post hoc analysis evidenced a significant reduction of diastolic blood pressure following  
270 the PR-diet intervention, while uric acid decreased following the C-diet.

271 Overall, body weight and BMI measured along the study resulted different in the two treatment periods  
272 ( $p = 0.023$  and  $p = 0.017$ , respectively) being lower during C-diet intervention. Finally, a time effect  
273 ( $p = 0.039$ ) was observed for total cholesterol with a trend towards reduction following both  
274 interventions. No significant effect was found for the remaining variables.

275 Considering gender (**Table 3A and 3B, supplementary material**), a significant time effect was  
276 observed within men for TC ( $p = 0.003$ ), LDL-C ( $p = 0.020$ ) and the ratio TC/HDL-C ( $p = 0.039$ ), LSD  
277 test showed a significant reduction after the PR-diet but not the control diet. A significant treatment  
278 effect was found for AST ( $p = 0.042$ ) and CRP ( $p = 0.032$ ) that showed a trend towards a reduction  
279 following both interventions.

280 Regarding women, a treatment  $\times$  time interaction was evidenced for systolic ( $p = 0.042$ ) and diastolic  
281 blood pressure ( $p = 0.043$ ) showing a reduction after the PR-diet, but not after the C-diet. A significant  
282 effect of treatment was observed for triglycerides ( $p = 0.030$ ).

283

284 *3.6 Effect of intervention on IP and related markers*

285 In **Table 3** are reported the results on serum zonulin levels before and after each treatment. A  
286 significant treatment ( $p = 0.008$ ) and treatment  $\times$  time interaction ( $p = 0.025$ ) was observed showing a  
287 decrease in serum zonulin levels after the PR-diet. After stratifying by gender (**Table 3A and 3B,**  
288 **supplementary material**), significant treatment and treatment  $\times$  time interaction ( $p = 0.004$  and  $p =$   
289  $0.010$  respectively) were detected for women.

290 The analysis of data based on HSZ or LSZ highlighted the importance of baseline zonulin level as a  
291 significant contributor to the impact of the dietary intervention. In fact, HSZ subjects were those with  
292 the higher IP reduction ( $p = 0.026$ ) following PR-diet and a significant decrease of diastolic blood  
293 pressure ( $p = 0.01$ ), glucose levels ( $p = 0.049$ ) and a trend towards a reduction of IL-6 ( $p = 0.097$ );  
294 conversely a significant increase in uric acid levels ( $p = 0.03$ ) was found after C-diet (data not shown).  
295 After stratifying subjects by BMI (**Table 1**), a significant reduction of zonulin levels ( $p = 0.007$ ) and  
296 DBP ( $p = 0.024$ ) was observed after PR diet in the group with BMI higher than the median value.  
297 Additionally, a significant increase in uric acid and IL-6 serum levels ( $p = 0.027$  and  $p = 0.049$   
298 respectively) was found during the C-diet (data not shown).

299 Similarly, by considering HOMA-index (i.e. higher vs. lower depending on median basal values) as  
300 stratification factor, a significant reduction of serum zonulin levels ( $p = 0.027$ ) and DBP ( $p = 0.013$ )  
301 following the PR-diet and an increase ( $p = 0.027$ ) in uric acid after C-diet was observed (data not  
302 shown).

303

#### 304 **4. Discussion**

305 In this study, we have shown that modifying the diet of older subjects by including small portions of  
306 PR-products can positively affect IP, evaluated as serum zonulin concentrations. Interestingly, greater  
307 reductions in serum zonulin concentrations following the PR-diet were observed in the HSZ sub-group,  
308 which was accompanied by decreases in diastolic blood pressure, glucose and IL-6 levels (even if the  
309 latter was not statistically significant). This supports the notion that the efficacy of PR-diet could  
310 depend on the baseline IP condition here evaluated as zonulin level. Zonulin, also known as  
311 prehaptoglobin-2, is a 47-kDa protein produced mainly by epithelial cells (e.g. in the gut) which is able  
312 to reversibly modulate paracellular permeability [27]. In fact, zonulin is a fundamental regulator of  
313 intercellular junctions since it can bind the epidermal growth factor receptor through the activation of  
314 protease-activated receptor 2. The derived complex induces the signalling pathway causing tight  
315 junction disassembly (induced by the phosphorylation of zonula occludens proteins) thus enabling the

316 paracellular passage of factors between the luminal environment and the inner part of the mucosa. For  
317 this reason, zonulin has been considered as a good (surrogate) marker of impaired intestinal barrier  
318 function and increased IP as it happens in different physiological and pathological conditions [18].  
319 Moreover, several studies have reported correlations between the results obtained through the most  
320 common and validated IP test (based on lactulose/mannitol urine excretion evaluation following  
321 standardised sugar intake) and those with serum zonulin levels [17,28-31].

322 Increased serum zonulin levels and impaired IP condition have been previously found in individuals  
323 with metabolic disorders, such as diabetes and obesity [28]. In this regard, we documented a significant  
324 association between serum zonulin levels and HOMA index at baseline in subjects classified in the  
325 HSZ group but not in the LSZ group suggesting an important contribution of zonulin in discriminating  
326 subjects suffering metabolic dysregulation [28].

327 Similarly, we observed a more pronounced IP reduction after the PR-diet in subjects with higher BMI  
328 and HOMA index at baseline, which supports the hypothesis of a link between IP and metabolic  
329 disorders.

330 Previous studies have also reported that leaky gut can play a significant role in age-related  
331 inflammation and frailty. Interestingly, Qi et al [32] found, in a preliminary exploratory study, higher  
332 serum zonulin levels in older subjects with respect to young ones. Moreover, a positive association  
333 between zonulin levels and markers of inflammation (TNF- $\alpha$ , IL-6) was shown, and an inverse one  
334 with physical performance (muscle strength and steps/day). In another study, higher levels of zonulin  
335 were associated with gastrointestinal symptoms and psychological distress suggesting the contribution  
336 of IP to these signs that are frequently found in the older population [33].

337 It has been suggested that increased serum zonulin levels also reflect the host response to an  
338 inflammatory process, suggesting that a two-way interaction can be present between inflammation and  
339 IP [34]. This is also supported by the observation of increased IP in most of the inflammation-related  
340 diseases both at intestinal (e.g. inflammatory bowel disease, irritable bowel syndrome, celiac disease)



341 and systemic levels (e.g. obesity, type 2-diabetes) including the age-related low-grade systemic  
342 inflammation [35].

343 The study of the inflammatory state is complex, because each of the available inflammatory markers  
344 provide different information on a multifaceted process that is dependent on the triggers and is  
345 modulated by both the host and environmental conditions. One of the most used markers is the C-  
346 reactive protein (CRP) which is considered a hallmark for inflammation and a sensitive risk factor for  
347 cardiovascular diseases. CRP is one of the major acute proteins phase reactants secreted in response to  
348 increased levels of inflammatory cytokines such as IL-6, interleukin-1 $\beta$  and TNF- $\alpha$ . High levels of  
349 serum CRP, IL-6 and TNF- $\alpha$  have been reported in smokers, obese subjects, diabetics and older adults  
350 [36]. In our experimental conditions, we documented that the 8-week intervention with the PR-diet  
351 failed to modulate inflammatory markers, in line with other intervention studies with polyphenol-rich  
352 foods both in adults and older individuals [37-42]. Other clinical trials providing tart cherry juice,  
353 supplements of resveratrol, freeze-dried strawberries, purée and dried bilberries or juice for different  
354 time periods (from 4 to 26 weeks of intervention) observed an effect on inflammation strictly dependent  
355 on the markers analysed, the trial characteristics and the target subjects considered [43-48].

356 With regard to the vascular function markers, it is well known that vascular oxidative stress increases  
357 with age and different studies found elevated levels of both VCAM-1 and ICAM-1 in older compared  
358 to younger individuals [49-50]. High polyphenol intake has been inversely associated with a reduced  
359 risk of cardiovascular events and mortality [51], possibly by decreasing the levels of reactive oxygen  
360 species and adhesion molecules or by inducing the production of vasodilators [52]. In the present study,  
361 we could not demonstrate an effect of the PR dietary pattern in terms of modulation of ICAM-1 and  
362 VCAM-1 as it has been previously documented following an intervention with freeze-dried wild  
363 blueberry drink, freeze-dried polyphenol-rich whole grape powder, green tea extract or beverage [37-  
364 39]. However, a protective effect was found by other research groups following the administration of  
365 different berries and grape products [53-54]. Nevertheless, no specific information on direct association  
366 between IP and vascular function has been previously reported.

367 The aging process is not only associated to a physiological alteration of blood vessels and vascular  
368 function but also with increasing systolic blood pressure. Therefore, hypertension, in particular systolic  
369 hypertension is very common in older subjects representing a major risk factor for cardiovascular  
370 disease and strokes [54]. Data from the literature suggest a potential role of polyphenols and  
371 polyphenol-rich foods in the modulation of blood pressure [55]. In the present study, most of the  
372 subjects showed normal blood pressure levels or a mild hypertension treated with drugs [56]. The PR-  
373 diet intervention significantly reduced diastolic blood pressure in both men and women. Our results  
374 are partially in line with that of other studies reporting partial or no effects of these foods on blood  
375 pressure [57-64]. In addition, it is noteworthy to highlight that we found also a significant reduction of  
376 systolic blood pressure in women, but not in men. In this regard, the impact of gender in the response  
377 to treatments of hypertension has been recently reviewed underlying the kidneys, renin-angiotensin  
378 system, relaxin, and developmental programming as potential contributors to the differences observed  
379 [65].

380 Aging is associated with numerous physiological dysfunctions at cellular and tissue levels, including  
381 deregulation of lipids and glucose metabolism. Dietary polyphenols seem to play a role in the  
382 regulation of glucose homeostasis, insulin sensitivity and lipid metabolism [51,66,67]. In our study the  
383 PR-diet did not modify glucose and lipid parameters, apart from a reduction trend in total and LDL-C.  
384 Similar findings were observed for tea and tea extracts [68-70], orange juice/hesperidin [64],  
385 pomegranate [66,67] and different fruit juices [71]. On the contrary, beneficial effects were  
386 documented following the consumption of cocoa products, dark chocolate, and flavan-3-ols [58,72,73],  
387 berries [74,75] and black cumin [76,77]. Nevertheless, despite the overall lack of significant effect of  
388 the PR-diet on metabolic features of the host, the degree of IP at baseline was found to affect the impact  
389 of the treatment on glucose levels, which was significantly reduced only in the HSZ group, as  
390 previously discussed. It is also interesting that a decrease in TC and LDL-CHOL was only found in  
391 men together with a significant decrease in CRP levels. However, the small sample size may represent

392 a limitation not enabling a strong emphasis on a potential gender specific response to the dietary  
393 treatment.

394 Overall, the main outcome of the MaPLE RCT is evidence that support the notion that IP reduction  
395 can be obtained through a sustainable inclusion in the diet of polyphenol-rich food sources and this  
396 may support also the reliability of non-invasive dietary intervention as potential strategies to improve  
397 IP in the older subjects. It is noteworthy that only limited research has been carried out to provide  
398 evidence for the efficacy of dietary treatments in the management of IP [2], and just one observation  
399 was recently published considering both healthy adults and older subjects as target population;  
400 although that, the study did not find an effect of dietary fibre (i.e. sugar beet derived pectins) on  
401 multiple IP parameters [78]. In the present trial, with respect to that by Wilms et al. [78], the inclusion  
402 of PR products, the type, duration and strict control of dietary intervention (i.e. compliance to  
403 polyphenol-rich products intake and overall dietary plan during the whole intervention study) and  
404 subjects' characteristics could have been reasons to explain the difference in the results obtained.  
405 Finally, since older subjects are generally low consumers of dietary fibre, the possibility to introduce  
406 other beneficial molecules could be of utmost importance for the exploitation directed to the  
407 maintenance of host functional and metabolic homeostasis.

408 The MaPLE study has several strengths represented by the well-controlled protocol of intervention  
409 including the setting, the daily preparation of products and the continuous interaction with the  
410 participants. On the other hand, it has also some limitations related mainly to the relatively small  
411 sample size. Furthermore, the evaluation of IP using also the gold standard method (i.e. multi-sugar  
412 test, difficult to apply in the population under study) or multiple IP markers could have provided more  
413 insight on the impact of the diet on this condition.

414

## 415 **5. Conclusions**

416 In conclusion, the MaPLE RCT has demonstrated the feasibility and efficacy of a PR dietary pattern,  
417 providing approximately 700 mg of total polyphenols daily for 8 weeks, in the modulation of IP

418 evaluated by means of serum zonulin levels and on limited associated markers. These results are novel  
419 and have potentially important clinical implications. Further intervention studies should be performed  
420 aimed at investigating the role of non-pharmacological treatment in the management of IP.

421

#### 422 **Authors' contributions**

423 PR and SG designed the trial and in collaboration with AC, CAL and PAK optimised the study protocol  
424 including the selection of clinical and biochemical markers and the development of the polyphenol-  
425 rich diet. CDB contributed to the development of the study protocol and with PR, SG and SB drafted  
426 the first version of the manuscript. CDB and SB performed the analysis of zonulin, VCAM-1 and  
427 ICAM-1. BK and MSW performed the evaluation of inflammatory markers. GG performed the  
428 statistical analysis in collaboration with RGD and GP. MP, NHL and RZR contributed to the  
429 elaboration of dietary polyphenol intake. All the authors critically revised the draft and approved the  
430 final version.

431

#### 432 **Conflict of interest**

433 The authors declare no conflicts of interest.

434

435

#### 436 **Acknowledgments**

437 This work was completed as part of the MAPLE project (Gut and Blood Microbiomics for Studying  
438 the Effect of a Polyphenol-Rich Dietary Pattern on Intestinal Permeability in the Elderly) supported  
439 within the European Joint Programming Initiative “A Healthy Diet for a Healthy Life” (JPI HDHL,  
440 [http:// www.healthydietforhealthylife.eu/](http://www.healthydietforhealthylife.eu/)) granted by Mipaaft (Italy, D.M. 8245/7303/ 2016),  
441 MINECO (Spain, PCIN-2015-238), and BBSRC (U.K., BB/R012512/1). Cristina Andres-Lacueva was  
442 also supported by grant 2017SGR1546 from the Generalitat de Catalunya’s Agency AGAUR, funds  
443 from CIBERFES (co-funded by the FEDER Program from the European Union), and ICREA

444 Academia Award 2018. Additional funding was provided by the Biotechnology and Biological  
445 Sciences Research Council (UK) through an Institute Strategic Programme Grant ('Food Innovation  
446 and Health'; Grant No. BB/R012512/1 1 and its constituent projects BBS/E/F/000PR10343 (Theme 1,  
447 Food Innovation) and BBS/E/F/000PR10346 (Theme 3, Digestion and Fermentation in the Lower GI  
448 Tract) to the Quadram Institute Bioscience. Raúl González-Domínguez thanks the "Juan de la Cierva"  
449 program from MINECO (FJCI-2015-26590). Raul Zamora-Ros was supported by the "Miguel Servet"  
450 program (CP15/00100) from the Institute of Health Carlos III (Co-funded by the European Social Fund  
451 (ESF) - ESF investing in your future). Cristian Del Bo' was supported by "Piano di sostegno alla  
452 ricerca- Linea 2, azione A-grant number PSR2019- CDELB and PSR2018-CDELB".

453 We sincerely thank all the volunteers for their valuable contribution and dedication to the study. We  
454 are grateful to the nursing and medical staff working at Opera Immacolata Concezione (OIC  
455 Foundation, Padua, Italy) for their coordinating activities in the nursing home and for the success of  
456 the study. In particular we would like to acknowledge Alberto Fantuzzo, Chiara Cavazzini, Lorella  
457 Pinton, Paolo Bergantin, Rosanna Ceccato, Pamela Soranzo, and Silvana Giraldini. We are also  
458 grateful to all the physicians (Michela Rigon, Lorena D'Aloise, Antonio Merlo, Elisabetta  
459 Bernardinello, Nadia Malacarne, Silvana Bortoli, Fabiola Talato, Agostino Corsini, Maria Licursi,  
460 Nicoletta Marcon, Angela Sansone), the nurses and other personnel at OIC who were essential to  
461 complete the study successfully. In addition, we would like to thank Giulia Minto and Nicola Fassetta  
462 for their help during the intervention period. Finally, the authors are grateful to Barry Callebaut, Indena,  
463 Melinda, Oranfrizer, Roberts Berrie, Zuegg for their in-kind contribution of the products.

464

#### 465 **Supplementary data**

466 Table 3A and 3B are provided as supplementary material.

467 **Figure 1: Consort flow diagram**

468

469 **Figure 2 – Correlations between the different markers at baseline in the whole group of older**  
470 **subjects (A), in HSZ subjects (serum zonulin levels > median) (B) and LSZ subjects (serum**  
471 **zonulin levels ≤ median) (C)**

472 The heatmap represents the R value of Spearman's correlation. Asterisks indicate the Kendall rank  
473 correlation: \*  $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

474

475 Legend: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, Total  
476 cholesterol, HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol;  
477 TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-  
478 glutamyl transpeptidase; HOMA index, homeostasis model assessment index; C-G index, Cockcroft-  
479 Gault index; sVCAM-1, vascular cells adhesion molecules-1; ICAM-1, intercellular cells adhesion  
480 molecules-1; CRP, C-reactive protein; TNF- $\alpha$ , tumour necrosis factor - $\alpha$ ; IL-6, interleukin-6

481 **6. References**

- 482 [1] Lee SH. Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory  
483 Bowel Diseases. *Intest Res* 2015;13:11. <https://doi.org/10.5217/ir.2015.13.1.11>.
- 484 [2] Bernardi S, Del Bo' C, Marino M, Gargari G, Cherubini A, Andres-Lacueva C, et al.  
485 Polyphenols and intestinal permeability: rationale and future perspectives. *J Agric Food Chem*  
486 2019;<https://doi.org/10.1021/acs.jafc.9b02283>. <https://doi.org/10.1021/acs.jafc.9b02283>.
- 487 [3] Fasano A. Leaky gut and autoimmune diseases. *Clin Rev Allergy Immunol* 2012;42:71–8.  
488 <https://doi.org/10.1007/s12016-011-8291-x>.
- 489 [4] Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D, Serino M, et al. Intestinal  
490 permeability—a new target for disease prevention and therapy. *BMC Gastroenterol*  
491 2014;14:189. <https://doi.org/10.1186/s12876-014-0189-7>.
- 492 [5] Nicoletti C. Age-associated changes of the intestinal epithelial barrier: local and systemic  
493 implications 2015. <https://doi.org/10.1586/17474124.2015.1092872>.
- 494 [6] Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, et al. Inflammaging  
495 2018: An update and a model. *Semin Immunol* 2018.  
496 <https://doi.org/10.1016/j.smim.2018.10.008>.
- 497 [7] Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, et al. An update on inflamm-  
498 aging: mechanisms, prevention, and treatment. *J Immunol Res* 2016.  
499 <https://doi.org/10.1155/2016/8426874>.
- 500 [8] Yu LC-H, Wang J-T, Wei S-C, Ni Y-H. Host-microbial interactions and regulation of  
501 intestinal epithelial barrier function: From physiology to pathology. *World J Gastrointest*  
502 *Pathophysiol* 2012;3:27. <https://doi.org/10.4291/wjgp.v3.i1.27>.
- 503 [9] Morkkala K, R yti  H, Munukka E, Pietil  S, Ekblad U, R nnemaa T, et al. Gut Microbiota  
504 Richness and Composition and Dietary Intake of Overweight Pregnant Women Are Related to  
505 Serum Zonulin Concentration, a Marker for Intestinal Permeability. *J Nutr* 2016;146:1694–  
506 700. <https://doi.org/10.3945/jn.116.235358>.

- 507 [10] Mörkl S, Lackner S, Meinitzer A, Mangge H, Lehofer M, Halwachs B, et al. Gut microbiota,  
508 dietary intakes and intestinal permeability reflected by serum zonulin in women. *Eur J Nutr*  
509 2018. <https://doi.org/10.1007/s00394-018-1784-0>.
- 510 [11] Ott B, Skurk T, Hastreiter L, Lagkouvardos I, Fischer S, Büttner J, et al. Effect of caloric  
511 restriction on gut permeability, inflammation markers, and fecal microbiota in obese women.  
512 *Sci Rep* 2017. <https://doi.org/10.1038/s41598-017-12109-9>.
- 513 [12] Rohr MW, Narasimhulu CA, Rudeski-Rohr TA, Parthasarathy S. Negative Effects of a High-  
514 Fat Diet on Intestinal Permeability: A Review. *Adv Nutr* 2019.  
515 <https://doi.org/10.1093/advances/nmz061>.
- 516 [13] Guerreiro CS, Calado Â, Sousa J. Diet , Microbiota , and Gut Permeability — The Unknown  
517 Triad in Rheumatoid Arthritis. *Front Med* 2018;5:1–7.  
518 <https://doi.org/10.3389/fmed.2018.00349>.
- 519 [14] Peron G, Hidalgo-Liberona N, González-Domínguez R, Garcia-Aloy M, Guglielmetti S,  
520 Bernardi S, et al. Exploring the Molecular Pathways behind the Effects of Nutrients and  
521 Dietary Polyphenols on Gut Microbiota and Intestinal Permeability: A Perspective on the  
522 Potential of Metabolomics and Future Clinical Applications. *J Agric Food Chem* 2019;doi:  
523 10.1021/acs.jafc.9b01687. <https://doi.org/10.1021/acs.jafc.9b01687>.
- 524 [15] Guglielmetti S, Bernardi S, Del Bo' C, Cherubini A, Porrini M, Gargari G., et al. Effect of a  
525 polyphenol-rich dietary pattern on intestinal permeability and gut and blood microbiomes in  
526 older subjects: study protocol of the MaPLE randomised controlled trial. *BMC Geriatr*  
527 2020;20:70. <https://doi.org/10.1186/s12877-020-1472-9>.
- 528 [16] Li C, Gao M, Zhang W, Chen C, Zhou F, Hu Z, et al. Zonulin Regulates Intestinal  
529 Permeability and Facilitates Enteric Bacteria Permeation in Coronary Artery Disease. *Sci Rep*  
530 2016;6:29142. <https://doi.org/10.1038/srep29142>.
- 531 [17] Ciccia F, Guggino G, Rizzo A, Alessandro R, Luchetti MM, Milling S, et al. Dysbiosis and  
532 zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing



- 533 spondylitis. *Ann Rheum Dis* 2017;76:1123–32. <https://doi.org/10.1136/annrheumdis-2016->  
534 210000.
- 535 [18] Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernández-Real JM. Circulating  
536 zonulin, a marker of intestinal permeability, is increased in association with obesity-associated  
537 insulin resistance. *PLoS One* 2012;7:e37160. <https://doi.org/10.1371/journal.pone.0037160>.
- 538 [19] A Agbor G, Vinson JA, Donnelly PE. Folin-Ciocalteu Reagent for Polyphenolic Assay. *Int J*  
539 *Food Sci Nutr Diet* 2014;3:147–56. <https://doi.org/10.19070/2326-3350-1400028>.
- 540 [20] Lohman TJ, Roache AF, Martorell R. Anthropometric Standardization Reference Manual.  
541 *Med Sci Sport Exerc* 1992. <https://doi.org/10.1249/00005768-199208000-00020>.
- 542 [21] Chobanian A V., Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh  
543 report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of  
544 High Blood Pressure. *Hypertension* 2003;42:1206–52.  
545 <https://doi.org/10.1161/01.HYP.0000107251.49515.c2>.
- 546 [22] Knopfholz J, Disserol CCD, Pierin AJ, Schirr FL, Streisky L, Takito LL, et al. Validation of  
547 the friedewald formula in patients with metabolic syndrome. *Cholesterol* 2014;2014:261878.  
548 <https://doi.org/10.1155/2014/261878>.
- 549 [23] Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard JP. How can we  
550 measure insulin sensitivity/resistance? *Diabetes Metab* 2011;37:179–88.  
551 <https://doi.org/10.1016/j.diabet.2011.01.002>.
- 552 [24] Drinka, PJ, Langer E. The Cockcroft-Gault formula. *J Am Geriatr Soc* 1989;37.  
553 <https://doi.org/10.1111/j.1532-5415.1989.tb02250.x>
- 554 [25] Ferreira JP, Girerd N, Pellicori P, Duarte K, Girerd S, Pfeffer MA, et al. Renal function  
555 estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-  
556 based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart  
557 “OMics” in AGEing (HOMAGE) and the high-risk myocardial. *BMC Med* 2016.  
558 <https://doi.org/10.1186/s12916-016-0731-2>.

- 559 [26] Valentini L, Ramminger S, Haas V, Postrach E, Werich M, Fischer A, et al. Small intestinal  
560 permeability in older adults. *Physiol Rep* 2014;2:e00281. <https://doi.org/10.14814/phy2.281>.
- 561 [27] Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic  
562 implications. *Clin Gastroenterol Hepatol* 2012;10:1096–100.  
563 <https://doi.org/10.1016/j.cgh.2012.08.012>.
- 564 [28] Sapone A, De Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin  
565 upregulation is associated with increased gut permeability in subjects with type 1 diabetes and  
566 their relatives. *Diabetes* 2006;55:1443–9. <https://doi.org/10.2337/db05-1593>.
- 567 [29] Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal  
568 barrier function: May not be what it seems. *PLoS One* 2019.  
569 <https://doi.org/10.1371/journal.pone.0210728>.
- 570 [30] Bernardi, Del Bo', Guglielmetti, Cherubini, Kroon, Kirkup, et al. Role of a Polyphenol-Rich  
571 Dietary Pattern in the Modulation of Intestinal Permeability in Older Subjects: The MaPLE  
572 Study. *Proceedings* 2019. <https://doi.org/10.3390/proceedings2019011008>.
- 573 [31] Wegh CAM, De Roos NM, Hovenier R, Meijerink J, Besseling-Van Der Vaart I, Van Hemert  
574 S, et al. Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum  
575 Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission. *J Nutr Metab*  
576 2019. <https://doi.org/10.1155/2019/2472754>.
- 577 [32] Qi Y, Goel R, Kim S, Richards EM, Carter CS, Pepine CJ, et al. Intestinal permeability  
578 biomarker zonulin is elevated in healthy aging. *J Am Med Dir Assoc* 2017;18:810-e1.  
579 <https://doi.org/10.1016/j.jamda.2017.05.018>.
- 580 [33] Ganda Mall JP, Östlund-Lagerström L, Lindqvist CM, Algilani S, Rasoal D, Repsilber D, et al.  
581 Are self-reported gastrointestinal symptoms among older adults associated with increased  
582 intestinal permeability and psychological distress? *BMC Geriatr* 2018.  
583 <https://doi.org/10.1186/s12877-018-0767-6>.
- 584 [34] Zak-Golab A, Kocelak P, Aptekorz M, Zientara M, Juszczuk L, Martirosian G, et al. Gut

- 585 microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and  
586 normal weight subjects. *Int J Endocrinol* 2013;2013:674106.  
587 <https://doi.org/10.1155/2013/674106>.
- 588 [35] Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really  
589 Influence the Risk of Inflammation? *Inflamm Intest Dis* 2016.  
590 <https://doi.org/10.1159/000447252>.
- 591 [36] Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro CA, et al.  
592 Effects of natural aging and gender on pro-inflammatory markers. *Brazilian J Med Biol Res*  
593 2019. <https://doi.org/10.1590/1414-431x20198392>.
- 594 [37] Riso P, Klimis-Zacas D, Del Bo' C, Martini D, Campolo J, Vendrame S, et al. Effect of a wild  
595 blueberry (*Vaccinium angustifolium*) drink intervention on markers of oxidative stress,  
596 inflammation and endothelial function in humans with cardiovascular risk factors. *Eur J Nutr*  
597 2013. <https://doi.org/10.1007/s00394-012-0402-9>.
- 598 [38] Bardagjy AS, Hu Q, Giebler KA, Ford A, Steinberg FM. Effects of grape consumption on  
599 biomarkers of inflammation, endothelial function, and PBMC gene expression in obese  
600 subjects. *Arch Biochem Biophys* 2018. <https://doi.org/10.1016/j.abb.2018.04.003>.
- 601 [39] Basu A, Du M, Sanchez K, Leyva MJ, Betts NM, Blevins S, et al. Green tea minimally affects  
602 biomarkers of inflammation in obese subjects with metabolic syndrome. *Nutrition* 2011.  
603 <https://doi.org/10.1016/j.nut.2010.01.015>.
- 604 [40] Cory H, Passarelli S, Szeto J, Tamez M, Mattei J. The Role of Polyphenols in Human Health  
605 and Food Systems: A Mini-Review. *Front Nutr* 2018. <https://doi.org/10.3389/fnut.2018.00087>.
- 606 [41] Paquette M, Medina Larqué AS, Weisnagel SJ, Desjardins Y, Marois J, Pilon G, et al.  
607 Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-  
608 diabetic adults: A parallel, double-blind, controlled and randomised clinical trial. *Br. J. Nutr.*,  
609 2017. <https://doi.org/10.1017/S0007114517000393>.
- 610 [42] Curtis PJ, Van Der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, et al.

611 Blueberries improve biomarkers of cardiometabolic function in participants with metabolic  
612 syndrome-results from a 6-month, double-blind, randomized controlled trial. *Am J Clin Nutr*  
613 2019. <https://doi.org/10.1093/ajcn/nqy380>.

614 [43] Chai SC, Davis K, Wright RS, Kuczmarski MF, Zhang Z. Impact of tart cherry juice on  
615 systolic blood pressure and low-density lipoprotein cholesterol in older adults: A randomized  
616 controlled trial. *Food Funct* 2018. <https://doi.org/10.1039/c8fo00468d>.

617 [44] Veronica Witte A, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory  
618 performance, hippocampal functional connectivity, and glucose metabolism in healthy older  
619 adults. *J Neurosci* 2014. <https://doi.org/10.1523/JNEUROSCI.0385-14.2014>.

620 [45] Schumacher HR, Pullman-Mooar S, Gupta SR, Dinnella JE, Kim R, McHugh MP.  
621 Randomized double-blind crossover study of the efficacy of a tart cherry juice blend in  
622 treatment of osteoarthritis (OA) of the knee. *Osteoarthr Cartil* 2013.  
623 <https://doi.org/10.1016/j.joca.2013.05.009>.

624 [46] Moazen S, Amani R, Homayouni Rad A, Shahbazian H, Ahmadi K, Taha Jalali M. Effects of  
625 freeze-dried strawberry supplementation on metabolic biomarkers of atherosclerosis in  
626 subjects with type 2 diabetes: A randomized double-blind controlled trial. *Ann Nutr Metab*  
627 2013. <https://doi.org/10.1159/000356053>.

628 [47] Kolehmainen M, Mykkänen O, Kirjavainen P V., Leppänen T, Moilanen E, Adriaens M, et al.  
629 Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome.  
630 *Mol Nutr Food Res* 2012. <https://doi.org/10.1002/mnfr.201200195>.

631 [48] Karlsen A, Paur I, Bøhn SK, Sakhi AK, Borge GI, Serafini M, et al. Bilberry juice modulates  
632 plasma concentration of NF-κB related inflammatory markers in subjects at increased risk of  
633 CVD. *Eur J Nutr* 2010. <https://doi.org/10.1007/s00394-010-0092-0>.

634 [49] Herrera EA, Verkerk MM, Derks JB, Giussani DA. Antioxidant treatment alters peripheral  
635 vascular dysfunction induced by postnatal glucocorticoid therapy in rats. *PLoS One* 2010.  
636 <https://doi.org/10.1371/journal.pone.0009250>.


- 637 [50] Richter V, Rassoul F, Purschwitz K, Hentschel B, Reuter W, Kuntze T. Circulating vascular  
638 cell adhesion molecules VCAM-1, ICAM-1, and E-selectin in dependence on aging.  
639 *Gerontology* 2003. <https://doi.org/10.1159/000071710>.
- 640 [51] Del Bo' C, Bernardi S, Marino M, Porrini M, Tucci M, Guglielmetti S, et al. Systematic  
641 Review on Polyphenol Intake and Health Outcomes: Is there Sufficient Evidence to Define a  
642 Health-Promoting Polyphenol-Rich Dietary Pattern? *Nutrients* 2019;11:1355.  
643 <https://doi.org/10.3390/nu11061355>.
- 644 [52] Barona J, Aristizabal JC, Blesso CN, Volek JS, Fernandez ML. Grape polyphenols reduce  
645 blood pressure and increase flow-mediated vasodilation in men with metabolic syndrome. *J*  
646 *Nutr* 2012;142:1626–32. <https://doi.org/10.3945/jn.112.162743>.
- 647 [53] Lehtonen HM, Suomela JP, Tahvonen R, Yang B, Venojärvi M, Viikari J, et al. Different  
648 berries and berry fractions have various but slightly positive effects on the associated variables  
649 of metabolic diseases on overweight and obese women. *Eur J Clin Nutr* 2011.  
650 <https://doi.org/10.1038/ejcn.2010.268>.
- 651 [54] Chrysant SG. Aggressive systolic blood pressure control in older subjects: benefits and risks.  
652 *Postgrad Med* 2018. <https://doi.org/10.1080/00325481.2018.1433434>.
- 653 [55] Godos J, Vitale M, Micek A, Ray S, Martini D, Del Rio D, et al. Dietary Polyphenol Intake,  
654 Blood Pressure, and Hypertension: A Systematic Review and Meta-Analysis of Observational  
655 Studies. *Antioxidants (Basel, Switzerland)* 2019;8. <https://doi.org/10.3390/antiox8060152>.
- 656 [56] Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension.  
657 *Cochrane Database Syst Rev* 2012. <https://doi.org/10.1002/14651858.CD006742.pub2>.
- 658 [57] Peng X, Zhou R, Wang B, Yu X, Yang X, Liu K, et al. Effect of green tea consumption on  
659 blood pressure: A meta-analysis of 13 randomized controlled trials. *Sci Rep* 2014.  
660 <https://doi.org/10.1038/srep06251>.
- 661 [58] Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M, et al. Effect of cocoa  
662 products on blood pressure: Systematic review and meta-analysis. *Am J Hypertens* 2010.

- 663 <https://doi.org/10.1038/ajh.2009.213>.
- 664 [59] Li SH, Zhao P, Tian HB, Chen LH, Cui LQ. Effect of grape polyphenols on blood pressure: A  
665 meta-analysis of randomized controlled trials. *PLoS One* 2015.  
666 <https://doi.org/10.1371/journal.pone.0137665>.
- 667 [60] Martini D, Chiavaroli L, González-Sarrías A, Bresciani L, Palma-Duran SA, Dall’asta M, et  
668 al. Impact of foods and dietary supplements containing hydroxycinnamic acids on  
669 cardiometabolic biomarkers: A systematic review to explore inter-individual variability.  
670 *Nutrients* 2019. <https://doi.org/10.3390/nu11081805>.
- 671 [61] Zhu Y, Sun J, Lu W, Wang X, Wang X, Han Z, et al. Effects of blueberry supplementation on  
672 blood pressure: A systematic review and meta-analysis of randomized clinical trials. *J Hum  
673 Hypertens* 2017. <https://doi.org/10.1038/jhh.2016.70>.
- 674 [62] Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. *Cochrane Database Syst Rev*  
675 2017. <https://doi.org/10.1002/14651858.CD008893.pub3>.
- 676 [63] Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A  
677 meta-analysis. *BMC Med* 2010. <https://doi.org/10.1186/1741-7015-8-39>.
- 678 [64] Mohammadi M, Ramezani-Jolfaie N, Lorzadeh E, Khoshbakht Y, Salehi-Abargouei A.  
679 Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood  
680 pressure: A systematic review and meta-analysis of randomized controlled clinical trials.  
681 *Phyther Res* 2019. <https://doi.org/10.1002/ptr.6264>.
- 682 [65] Reckelhoff JF. Gender differences in hypertension. *Curr Opin Nephrol Hypertens* 2018.  
683 <https://doi.org/10.1097/MNH.0000000000000404>.
- 684 [66] Sahebkar A, Simental-Mendía LE, Giorgini P, Ferri C, Grassi D. Lipid profile changes after  
685 pomegranate consumption: A systematic review and meta-analysis of randomized controlled  
686 trials. *Phytomedicine* 2016. <https://doi.org/10.1016/j.phymed.2015.12.014>.
- 687 [67] Huang H, Liao D, Chen G, Chen H, Zhu Y. Lack of efficacy of pomegranate supplementation  
688 for glucose management, insulin levels and sensitivity: Evidence from a systematic review and

- 689 meta-analysis. *Nutr J* 2017. <https://doi.org/10.1186/s12937-017-0290-1>.
- 690 [68] Araya - Quintanilla F, Gutiérrez - Espinoza H, Moyano – Gálvez V, Muñoz – Yáñez MJ,  
691 Pavez L, García K. Effectiveness of black tea versus placebo in subjects with  
692 hypercholesterolemia: A PRISMA systematic review and meta-analysis. *Diabetes Metab*  
693 *Syndr Clin Res Rev* 2019. <https://doi.org/10.1016/j.dsx.2019.05.019>.
- 694 [69] Li X, Wang W, Hou L, Wu H, Wu Y, Xu R, et al. Does tea extract supplementation benefit  
695 metabolic syndrome and obesity? A systematic review and meta-analysis. *Clin Nutr* 2019.  
696 <https://doi.org/10.1016/j.clnu.2019.05.019>.
- 697 [70] Zhao Y, Asimi S, Wu K, Zheng J, Li D. Black tea consumption and serum cholesterol  
698 concentration: Systematic review and meta-analysis of randomized controlled trials. *Clin Nutr*  
699 2015. <https://doi.org/10.1016/j.clnu.2014.06.003>.
- 700 [71] Murphy MM, Barrett EC, Bresnahan KA, Barraj LM. 100 % Fruit juice and measures of  
701 glucose control and insulin sensitivity: a systematic review and meta-analysis of randomised  
702 controlled trials. *J Nutr Sci* 2017. <https://doi.org/10.1017/jns.2017.63>.
- 703 [72] Jia L, Liu X, Bai YY, Li SH, Sun K, He C, et al. Short-term effect of cocoa product  
704 consumption on lipid profile: A meta-analysis of randomized controlled trials. *Am J Clin Nutr*  
705 2010. <https://doi.org/10.3945/ajcn.2009.28202>.
- 706 [73] Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, et al. Effects of chocolate,  
707 cocoa, and flavan-3-ols on cardiovascular health: A systematic review and meta-analysis of  
708 randomized trials. *Am J Clin Nutr* 2012. <https://doi.org/10.3945/ajcn.111.023457>.
- 709 [74] Luís Â, Domingues F, Pereira L. Association between berries intake and cardiovascular  
710 diseases risk factors: A systematic review with meta-analysis and trial sequential analysis of  
711 randomized controlled trials. *Food Funct* 2018. <https://doi.org/10.1039/c7fo01551h>.
- 712 [75] Huang H, Chen G, Liao D, Zhu Y, Xue X. Effects of Berries Consumption on Cardiovascular  
713 Risk Factors: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled  
714 Trials. *Sci Rep* 2016. <https://doi.org/10.1038/srep23625>.

- 715 [76] Askari G, Rouhani MH, Ghaedi E, Ghavami A, Nouri M, Mohammadi H. Effect of *Nigella*  
716 *sativa* (black seed) supplementation on glycemic control: A systematic review and meta-  
717 analysis of clinical trials. *Phyther Res* 2019. <https://doi.org/10.1002/ptr.6337>.
- 718 [77] Sahebkar A, Beccuti G, Simental-Mendía LE, Nobili V, Bo S. *Nigella sativa* (black seed)  
719 effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of  
720 randomized placebo-controlled trials. *Pharmacol Res* 2016.  
721 <https://doi.org/10.1016/j.phrs.2016.02.008>.
- 722 [78] Wilms E, Jonkers DMAE, Savelkoul HFJ, Elizalde M, Tischmann L, Vos P de, et al. The  
723 impact of pectin supplementation on intestinal barrier function in healthy young adults and  
724 healthy elderly. *Nutrients* 2019;11:1–16. <https://doi.org/10.3390/nu11071554>.
- 725 [79] Makki K, Deehan EC, Walter J, Bäckhed F. The Impact of Dietary Fiber on Gut Microbiota in  
726 Host Health and Disease. *Cell Host Microbe* 2018.  
727 <https://doi.org/10.1016/j.chom.2018.05.012>.
- 728










2C



**Table 1 – Baseline characteristics of subjects selected for the study**

Variables	Median (IQR)	Mean (SD)
Age (y)	77 (70;87)	78.0 ± 10.3
Body weight (kg)	73.6 (62;83)	73.1 ± 14.0
BMI (kg/m <sup>2</sup> )	25.7 (22.5;30.7)	26.8 ± 5.5
SBP (mm Hg)	125 (120;130)	125.6 ± 10.8
DBP (mm Hg)	75 (70;80)	74.5 ± 8.2
Glucose (mg/dL)	95 (86;113)	113.5 ± 67.2
Creatinine (mg/dL)	0.87 (0.62;1.05)	0.9 ± 0.29
Uric Acid (mg/dl)	5.10 (4.20;6.60)	5.5 ± 1.76
TC (mg/dL)	194 (167;242)	196.3 ± 50.1
HDL-C (mg/dL)	45 (37;55)	46.5 ± 14.9
LDL-C (mg/dL)	120 (85;146)	120.5 ± 36.7
TC/HDL-C (ratio)	4.18 (3.54;5.43)	4.45 ± 1.17
LDL/HDL-C (ratio)	2.57 (2.08;3.45)	2.72 ± 0.76
TG (mg/dL)	117 (89;169)	146.1 ± 93.4
AST (U/L)	17 (13;22)	17.8 ± 5.7
ALT (U/L)	11 (8;19)	13.4 ± 7.2
GGT (U/L)	23 (17;46)	38.1 ± 39.0
Insuline uU/mL	6.20 (4.70;9.20)	8.4 ± 6.4
HOMA index	1.55 (1.15;2.50)	2.9 ± 5.4
C-G index	69.4 (53.7;82.5)	74.8 ± 40.5
Zonulin (ng/mL)	40 (34.5;49.2)	42.2 ± 11.8
sVCAM-1 (ng/mL)	967.9 (628.0;1327.1)	1239 ± 1683

sICAM-1 (ng/mL)	51.4 (43.9;65.4)	55.6 ± 20.5
CRP (mg/L)	3.5 (1.6;9.8)	7.02 ± 8.0
TNF- $\alpha$ (pg/mL)	1.2 (1.0;1.8)	1.6 ± 1.2
IL-6 (pg/mL)	3.1 (1.9;5.4)	4.5 ± 4.1

---

All data are presented as median and interquartile range (IQR) and as mean  $\pm$  standard deviation (SD). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, Total cholesterol, HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; HOMA index, homeostasis model assessment index; C-G index, Cockcroft-Gault, sVCAM-1, vascular cells adhesion molecules-1; ICAM-1, intercellular cells adhesion molecules-1; CRP, C-reactive protein; TNF- $\alpha$ , tumour necrosis factor-alpha; IL-6, interleukin-6

**Table 2 – Effect of intervention on nutrient and polyphenol intake**

Variables	PR- diet	C diet	P value
Energy (Kcal)	1537 ± 183	1559 ± 153	0.365
Total carbohydrates (% of energy)	47.2 ± 5.4	45.2 ± 5.2	0.016
Protein (% of energy)	17.7 ± 1.8	18.0 ± 1.9	0.185
Animal proteins (% of energy)	66.5 ± 8.2	68.9 ± 7.3	0.013
Vegetable proteins (% of energy)	27.3 ± 6.5	28.7 ± 6.8	0.100
Total lipids (% of energy)	34.9 ± 4.7	36.9 ± 4.7	0.012
SFA (% of energy)	11.3 ± 2.3	11.8 ± 2.5	0.179
MUFA (% of energy)	15.2 ± 2.8	16.4 ± 2.7	0.012
PUFA (% of energy)	3.2 ± 0.8	4.0 ± 1.5	<0.001
ω-3 (% of energy)	0.6 ± 0.2	0.6 ± 0.2	0.291
ω-6 (% of energy)	2.6 ± 0.7	3.4 ± 1.3	<0.001
Total Fibre (g/1000 kcal)	11.4 ± 1.8	10.5 ± 1.8	0.005
Cholesterol (mg)	216.3 ± 62.2	210.8 ± 67.0	0.587
Total carbohydrates (g)	188.6 ± 24.2	184.2 ± 27.0	0.286
Proteins (g)	66.7 ± 10.5	68.9 ± 8.7	0.063
Animal proteins (g)	45.0 ± 9.8	48.0 ± 8.7	0.003
Vegetable proteins (g)	17.7 ± 3.8	19.3 ± 3.7	0.001
Total lipids (g)	59.1 ± 13.3	63.1 ± 11.3	0.040
SFA (g)	19.2 ± 5.5	20.3 ± 5.3	0.209
MUFA (g)	26.0 ± 5.5	28.6 ± 6.0	0.004
PUFA (g)	5.6 ± 2.0	6.9 ± 2.6	<0.001
Total ω-3 (g)	1.0 ± 0.4	1.1 ± 0.4	0.315
Total ω-6 (g)	4.5 ± 1.7	5.7 ± 2.3	<0.01

Fibre (g/day)	17.4 ± 3.3	16.4 ± 3.2	0.006
Calcium (mg)	736.9 ± 207.7	875.0 ± 233.2	<0.001
Iron (mg)	8.5 ± 1.7	9.2 ± 1.6	0.003
Vitamin B <sub>12</sub> (µg)	6.2 ± 6.5	5.4 ± 6.3	0.537
Vitamin C (mg)	128.8 ± 47.2	111.7 ± 40.1	0.012
Vitamin E (mg)	8.5 ± 2.2	8.9 ± 2.3	0.366
Vitamin B <sub>1</sub> (mg)	0.9 ± 0.2	0.9 ± 0.2	0.123
Folates (µg)	233.3 ± 66.0	250.8 ± 72.7	0.126
Vitamin B <sub>6</sub> (mg)	1.4 ± 0.3	1.5 ± 0.3	0.079
Total Polyphenols (mg/day)	1391.2 ± 188.1	812.3 ± 193.1	<0.001

---

All data are expressed as mean ± standard deviation (SD); Data with P<0.05 are significantly different. PR, polyphenol-rich diet; C, control diet; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; ω-3, omega-3 fatty acids; ω-6, omega-6 fatty acids



**Table 3- Effect of 8-week intervention with PR-diet and C-diet on anthropometrical, physical, biochemical, functional characteristics and serum zonulin levels in the whole group of subjects**

Variables	Before	After	Before	After	P for	P for	P for
(n = 51)	PR-diet	PR-diet	C diet	C diet	T	t	T x t
Body weight (kg)	73.4 ± 14.5	73.7 ± 14.6	72.8 ± 13.7	72.6 ± 13.9	0.023	0.779	0.126
BMI (kg/m <sup>2</sup> )	26.9 ± 5.7	27.0 ± 5.7	26.7 ± 5.4	26.6 ± 5.6	0.017	0.677	0.090
SBP (mmHg)	127.2 ± 12.7	124.5 ± 14.6	126.5 ± 9.8	126.2 ± 10.4	0.749	0.107	0.234
DBP (mmHg)	76.7 ± 8.6	73.8 ± 9.4	75.5 ± 6.8	76.9 ± 7.5	0.345	0.285	0.024
Glucose (mg/dL)	114.4 ± 68.2	107.4 ± 42.8	108.6 ± 42.3	105.7 ± 38.2	0.163	0.096	0.360
Creatinine (mg/dL)	0.89 ± 0.29	0.89 ± 0.32	0.89 ± 0.35	0.87 ± 0.31	0.386	0.220	0.422
Uric Acid (mg/dL)	5.6 ± 1.8	5.7 ± 1.7	5.8 ± 1.9	5.5 ± 1.7	0.793	0.361	0.034
TC (mg/dL)	194.9 ± 51.1	189.5 ± 49.7	191.6 ± 49.2	188.1 ± 50.9	0.411	0.039	0.700
HDL (mg/dL)	47.1 ± 14.6	46.6 ± 14.0	47.0 ± 14.9	46.9 ± 15.6	0.876	0.607	0.695
LDL (mg/dL)	119.3 ± 36.6	115.4 ± 33.9	116.4 ± 35.3	114.1 ± 36.9	0.321	0.054	0.646
TC/HDL (ratio)	4.3 ± 1.2	4.2 ± 1.0	4.3 ± 1.1	4.2 ± 1.1	0.610	0.107	0.511
LDL/HDL-C (ratio)	2.6 ± 0.7	2.6 ± 0.7	2.6 ± 0.7	2.6 ± 0.7	0.426	0.238	0.775

TG (mg/dL)	140.2 ± 86.9	136.9 ± 76.3	141.6 ± 91.7	135.6 ± 92.9	0.992	0.285	0.781
AST (U/L)	17.7 ± 5.4	17.4 ± 5.2	17.7 ± 5.3	17.9 ± 5.3	0.632	0.840	0.509
ALT (U/L)	13.7 ± 7.2	13.2 ± 6.6	13.5 ± 6.8	13.9 ± 6.5	0.656	0.831	0.382
GGT (U/L)	38.7 ± 31.9	37.1 ± 30.7	38.8 ± 39.6	36.8 ± 29.0	0.954	0.354	0.903
Insuline (uU/mL)	8.3 ± 6.6	7.2 ± 3.6	8.4 ± 6.7	7.3 ± 4.4	0.467	0.068	0.639
HOMA index	2.9 ± 5.5	2.0 ± 1.9	2.7 ± 4.6	2.1 ± 2.2	0.153	0.145	0.810
C-G index	72.8 ± 36.0	74.8 ± 40.5	74.3 ± 40.8	74.6 ± 38.7	0.494	0.189	0.449
sVCAM-1 (ng/mL)	980.4 ± 527.8	1037.4 ± 683.9	1319.9 ± 1713.2	1094.4 ± 703.0	0.095	0.462	0.197
sICAM-1 (ng/mL)	54.9 ± 20.5	59.9 ± 28.8	57.9 ± 23.8	55.7 ± 22.8	0.665	0.352	0.600
CRP (mg/L)	6.8 ± 8.7	5.9 ± 7.6	5.0 ± 5.6	6.3 ± 7.7	0.364	0.846	0.158
TNF- $\alpha$ (pg/mL)	1.5 ± 1.1	1.4 ± 0.6	1.4 ± 0.7	1.4 ± 0.6	0.148	0.376	0.562
IL-6 (pg/mL)	4.5 ± 3.7	4.3 ± 5.1	4.2 ± 3.8	5.3 ± 9.3	0.500	0.628	0.189
Zonulin (ng/mL)	41.9 ± 10.4	39.0 ± 8.9	42.8 ± 10.9	44.3 ± 12.5	0.008	0.462	0.025

---

All data are expressed as mean  $\pm$  standard deviation (SD). Data with  $P < 0.05$  are significantly different. T: treatment effect; t: time effect; T  $\times$  t: treatment  $\times$  time interaction.

PR, polyphenol-rich diet; C, control diet; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, Total cholesterol, HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; HOMA index, homeostasis model assessment index; C-G index, Cockcroft-Gault index; sVCAM-1, vascular cells adhesion molecules-1; ICAM-1, intercellular cells adhesion molecules-1; CRP, C-reactive protein; TNF- $\alpha$ , tumour necrosis factor  $\alpha$ ; IL-6, interleukin-6



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2,3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	4,5
	2b	Specific objectives or hypotheses	5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5,6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6,7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7,8,9
	6b	Any changes to trial outcomes after the trial commenced, with reasons	/
Sample size	7a	How sample size was determined	9,10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	7

		assessing outcomes) and how	
Statistical methods	11b	If relevant, description of the similarity of interventions	/
	12a	Statistical methods used to compare groups for primary and secondary outcomes	9,10
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	9,10
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10-13
	13b	For each group, losses and exclusions after randomisation, together with reasons	10,11
Recruitment	14a	Dates defining the periods of recruitment and follow-up	/
	14b	Why the trial ended or was stopped	/
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	11
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	/
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	/
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	/
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	10-13
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	/
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	17,18
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	18
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	14-18
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	2
Protocol	24	Where the full trial protocol can be accessed, if available	/
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	19

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

1 **Table 3A- Effect of 8-week intervention with PR-diet and C-diet on anthropometrical, physical, biochemical, functional markers and serum**  
 2 **zonulin levels in women**

Women (n = 29)	Before	After	Before	After	P for	P for	P for
	PR-diet	PR-diet	C diet	C diet	T	t	T x t
Body weight (kg)	68.8 ± 13.8	69.0 ± 13.8	68.3 ± 12.8	68.2 ± 13.4	0.062	0.878	0.416
BMI (kg/m <sup>2</sup> )	27.0 ± 5.7	27.1 ± 5.7	26.9 ± 5.4	26.8 ± 5.7	0.071	0.785	0.416
SBP (mmHg)	125.4 ± 8.8	120.6 ± 12.3	124.8 ± 9.5	125.7 ± 8.3	0.089	0.165	0.042
DBP (mmHg)	74.6 ± 7.1	71.7 ± 9.2	73.5 ± 6.8	74.7 ± 7.0	0.362	0.299	0.043
Glucose (mg/dL)	117.1 ± 80.9	109.3 ± 50.2	113.2 ± 60.2	107.9 ± 47.8	0.375	0.167	0.698
Creatinine (mg/dL)	0.81 ± 0.31	0.83 ± 0.37	0.82 ± 0.40	0.78 ± 0.33	0.211	0.481	0.134
Uric Acid (mg/dL)	5.5 ± 2.0	5.5 ± 1.9	5.6 ± 2.2	5.2 ± 1.8	0.390	0.184	0.079
TC (mg/dL)	200.7 ± 54.7	201.7 ± 53.8	197.1 ± 51.5	194.5 ± 57.3	0.183	0.787	0.645
HDL-C (mg/dL)	49.2 ± 16.9	48.9 ± 16.2	48.9 ± 17.0	48.8 ± 18.1	0.764	0.813	0.945
LDL-C (mg/dL)	121.3 ± 39.5	121.3 ± 36.8	119.6 ± 36.5	117.4 ± 41.2	0.341	0.608	0.691
TC/HDL (ratio)	4.4 ± 1.2	4.4 ± 1.1	4.3 ± 1.2	4.3 ± 1.2	0.261	0.957	0.712
HDL/LDL-C (ratio)	2.6 ± 0.7	2.6 ± 0.8	2.6 ± 0.8	2.6 ± 0.8	0.614	0.999	0.234
TG (mg/dL)	149.3 ± 99.3	152.8 ± 86.5	142.8 ± 97.6	139.7 ± 92.0	0.030	0.973	0.593

AST (U/L)	17.4 ± 5.7	17.4 ± 5.9	16.8 ± 5.5	16.5 ± 4.4	0.180	0.731	0.732
ALT (U/L)	13.3 ± 8.2	12.7 ± 7.2	12.3 ± 6.1	12.2 ± 5.2	0.304	0.596	0.709
GGT (U/L)	32.7 ± 32.5	33.4 ± 30.6	36.7 ± 45.8	31.4 ± 26.7	0.621	0.449	0.257
Insuline (uU/mL)	8.8 ± 8.2	7.4 ± 4.3	9.3 ± 8.1	7.4 ± 4.8	0.711	0.092	0.785
HOMA index	3.5 ± 7.2	2.2 ± 2.3	3.3 ± 6.0	2.3 ± 2.7	0.790	0.181	0.593
C-G index	68.8 ± 32.4	69.0 ± 32.9	69.8 ± 33.1	71.1 ± 32.9	0.179	0.524	0.660
sVCAM-1 (ng/mL)	1025.1 ± 499.2	1097.8 ± 562.6	1609.0 ± 2172.6	1250.3 ± 773.9	0.066	0.467	0.208
sICAM-1 (ng/mL)	56.6 ± 18.7	59.9 ± 25.0	55.9 ± 20.8	54.1 ± 20.1	0.336	0.200	0.121
CRP (mg/L)	6.4 ± 7.8	6.0 ± 8.1	5.6 ± 6.4	8.3 ± 10.6	0.448	0.424	0.140
TNF- $\alpha$ (pg/mL)	1.7 ± 1.3	1.5 ± 0.6	1.5 ± 0.8	1.4 ± 0.6	0.303	0.266	0.583
IL-6 (pg/mL)	4.6 ± 3.3	5.0 ± 6.3	4.8 ± 4.4	6.7 ± 11.9	0.174	0.487	0.328
Zonulin (ng/mL)	41.0 ± 9.0	38.5 ± 9.5	42.3 ± 10.1	45.8 ± 10.0	0.004	0.694	0.010

4 All data are expressed as mean  $\pm$  standard deviation (SD); Data with  $P < 0.05$  are significantly different.  
5 T: treatment effect; t: time effect; T x t: treatment x time interaction  
6 PR, polyphenol-rich diet; C, control diet; BMI, body mass index; SBP, systolic blood pressure; DBP,  
7 diastolic blood pressure; TC, Total cholesterol, HDL-C, high density lipoprotein-cholesterol; LDL-C,  
8 low density lipoprotein-cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT, alanine  
9 aminotransferase; GGT, gamma-glutamyl transpeptidase; HOMA index, homeostasis model  
10 assessment index; C-G index, Cockcroft-Gault index; sVCAM-1, vascular cells adhesion molecules-  
11 1; ICAM-1, intercellular cells adhesion molecules-1; CRP, C-reactive protein; TNF- $\alpha$ , tumour necrosis  
12 factor - $\alpha$ ; IL-6, interleukin-6



13 **Table 3B - Effect of 8-week intervention with PR-diet and C-diet on anthropometrical, physical, biochemical, functional markers and serum**  
 14 **zonulin levels in men**

Men (n = 22)	Before	After	Before	After	P for	P for	P for
	PR-diet	PR-diet	C diet	C diet	T	t	T x t
Body weight (kg)	79.4 ± 13.6	79.8 ± 13.5	78.7 ± 12.7	78.4 ± 12.7	0.142	0.815	0.199
BMI (kg/m <sup>2</sup> )	26.6 ± 5.7	26.6 ± 5.8	26.5 ± 5.6	26.4 ± 5.5	0.228	0.436	0.125
SBP (mmHg)	129.6 ± 16.5	129.5 ± 16.1	128.6 ± 10.1	126.9 ± 12.8	0.536	0.432	0.600
DBP (mmHg)	79.3 ± 9.8	76.7 ± 9.0	78.0 ± 6.0	79.8 ± 7.2	0.558	0.683	0.073
Glucose (mg/dL)	110.8 ± 48.2	105 ± 31.6	102.5 ± 25.3	102.8 ± 20.4	0.295	0.358	0.317
Creatinine (mg/dL)	1.0 ± 0.2	1.0 ± 0.2	1.0 ± 0.2	1.0 ± 0.2	0.733	0.308	0.460
Uric Acid (mg/dL)	5.7 ± 1.4	5.9 ± 1.4	6.0 ± 1.5	6.0 ± 1.5	0.203	0.521	0.259
TC (mg/dL)	187.4 ± 45.9	173.4 ± 39.4	184.3 ± 46.2	179.7 ± 40.9	0.677	0.003	0.106
HDL-C (mg/dL)	44.4 ± 10.6	43.5 ± 10.0	44.5 ± 11.5	44.5 ± 11.5	0.597	0.616	0.522
LDL-C (mg/dL)	116.6 ± 33.1	107.7 ± 28.5	112.3 ± 34.0	109.8 ± 30.6	0.714	0.020	0.954
TC/HDL-C (ratio)	4.33 ± 1.07	4.07 ± 0.80	4.26 ± 0.95	4.19 ± 1.05	0.829	0.039	0.284
LDL/HDL-C (ratio)	2.7 ± 0.7	2.5 ± 0.6	2.6 ± 0.6	2.5 ± 0.7	0.549	0.110	0.129
TG (mg/dL)	128.2 ± 67.7	115.9 ± 55.4	140.2 ± 85.5	130.2 ± 96	0.282	0.082	0.893

AST (U/L)	18.2 ± 5.0	17.5 ± 4.3	18.8 ± 5.0	19.6 ± 5.9	0.042	0.933	0.220
ALT (U/L)	14.3 ± 5.6	13.8 ± 5.9	15.2 ± 7.3	16.1 ± 7.4	0.074	0.729	0.387
GGT (U/L)	46.7 ± 30.0	42 ± 30.8	41.7 ± 30.4	43.8 ± 31.1	0.590	0.610	0.131
Insuline (uU/mL)	7.5 ± 3.3	6.9 ± 2.5	7.2 ± 4.0	7.2 ± 4.0	0.872	0.509	0.498
HOMA index	2.1 ± 1.1	1.8 ± 1.0	1.9 ± 1.2	1.8 ± 1.0	0.453	0.274	0.588
C-G index	78.0 ± 40.7	82.4 ± 48.4	80.2 ± 49.4	79.1 ± 45.7	0.694	0.156	0.125
sVCAM-1 (ng/mL)	921.6 ± 569.6	957.8 ± 824.6	939.0 ± 653.2	888.8 ± 547.8	0.737	0.920	0.724
sICAM-1 (ng/mL)	56.6 ± 23.0	60.0 ± 33.7	60.4 ± 27.7	57.9 ± 26.2	0.695	0.886	0.305
CRP (mg/L)	7.3 ± 9.9	5.7 ± 7.1	4.1 ± 4.5	3.7 ± 4.0	0.032	0.384	0.644
TNF- $\alpha$ (pg/mL)	1.3 ± 0.9	1.4 ± 0.5	1.2 ± 0.4	1.3 ± 0.5	0.218	0.721	0.859
IL-6 (pg/mL)	4.3 ± 4.1	3.4 ± 2.5	3.3 ± 2.6	3.3 ± 3.0	0.255	0.347	0.300
Zonulin (ng/mL)	43.1 ± 12.1	39.7 ± 8.1	43.5 ± 12.1	42.4 ± 15.2	0.409	0.141	0.497

15

16 All data are expressed as mean  $\pm$  standard deviation (SD). Data with P<0.05 are significantly different. T: treatment effect; t: time effect; T x t:

17 treatment x time interaction

18 PR, polyphenol-rich diet; C, control diet; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, Total cholesterol,

19 HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, triglycerides; AST, aspartate aminotransferase; ALT,

20 alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; HOMA index, homeostasis model assessment index; C-G index, Cockcroft-Gault

index; sVCAM-1, vascular cells adhesion molecules-1; ICAM-1, intercellular cells adhesion molecules-1; CRP, C-reactive protein; TNF- $\alpha$ , tumour necrosis factor  $\alpha$ ; IL-6, interleukin-6